Zacks: Analysts Expect VYNE Therapeutics Inc. (NASDAQ:VYNE) to Announce -$0.23 Earnings Per Share

Wall Street analysts expect that VYNE Therapeutics Inc. (NASDAQ:VYNE) will post ($0.23) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for VYNE Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.31). VYNE Therapeutics reported earnings of ($0.43) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 46.5%. The business is expected to report its next earnings report on Thursday, March 3rd.

According to Zacks, analysts expect that VYNE Therapeutics will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.41) to ($1.26). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.76) per share, with EPS estimates ranging from ($1.01) to ($0.53). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover VYNE Therapeutics.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). The firm had revenue of $4.09 million during the quarter, compared to analyst estimates of $4.67 million. VYNE Therapeutics had a negative return on equity of 128.61% and a negative net margin of 507.14%. During the same period in the prior year, the firm earned ($0.60) earnings per share.

A number of brokerages recently commented on VYNE. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of VYNE Therapeutics in a research report on Monday, December 6th. Zacks Investment Research downgraded VYNE Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 7th.

VYNE Therapeutics stock traded down $0.10 during trading on Friday, reaching $0.69. 6,242,427 shares of the company were exchanged, compared to its average volume of 2,757,209. VYNE Therapeutics has a 52-week low of $0.65 and a 52-week high of $13.20. The stock’s 50 day simple moving average is $1.12 and its two-hundred day simple moving average is $1.68.

Several large investors have recently added to or reduced their stakes in VYNE. Staley Capital Advisers Inc. boosted its position in shares of VYNE Therapeutics by 50.0% during the 2nd quarter. Staley Capital Advisers Inc. now owns 37,500 shares of the company’s stock worth $132,000 after acquiring an additional 12,500 shares in the last quarter. Principal Financial Group Inc. purchased a new position in shares of VYNE Therapeutics during the 2nd quarter worth approximately $42,000. Banque Cantonale Vaudoise purchased a new position in shares of VYNE Therapeutics during the 2nd quarter worth approximately $702,000. Deutsche Bank AG grew its holdings in shares of VYNE Therapeutics by 104.2% in the 2nd quarter. Deutsche Bank AG now owns 48,234 shares of the company’s stock worth $169,000 after acquiring an additional 24,611 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of VYNE Therapeutics in the 2nd quarter worth approximately $211,000. 27.07% of the stock is owned by institutional investors and hedge funds.

About VYNE Therapeutics

VYNE Therapeutics, Inc engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.

See Also: What are the disadvantages of after-hours trading?

Get a free copy of the Zacks research report on VYNE Therapeutics (VYNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VYNE Therapeutics (NASDAQ:VYNE)

Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.